In liver fibrosis and atherosclerosis it was shown that inhibiting CCL5 receptors through Met-RANTES was sufficient to reduce inflammation in mice (Veillard et al., 2004; Berres et al., 2010). This evidence concerns the gene CCL5 and atherosclerosis.